Philip Morris International Inc.
PM
$0.00
-4.84%
Philip Morris International Inc. is a global tobacco company focused on selling cigarettes and reduced-risk products primarily outside the US. It is a dominant player in the industry, leveraging its strong brand portfolio including Iqos and Zyn to transition towards smoke-free products.…
PM
Philip Morris International Inc.
$0.00
Related headlines
Investment Opinion: Should I buy PM Today?
Based on a synthesis of the data, the objective assessment for Philip Morris International (PM) is a Hold. The company's strong fundamentals, cash flow, and strategic positioning in growth categories are compelling. However, these positives are counterbalanced by high financial leverage, a premium valuation on certain metrics, and the persistent regulatory overhang of the tobacco industry. The stock appears fairly valued at its current forward P/E, making it more suitable for income-oriented investors willing to accept the sector's specific risks rather than a clear-cut growth opportunity.
Sign up to view all
PM 12-Month Price Forecast
The analysis yields a neutral stance. PM's powerful cash flows and strategic transition are foundational strengths, but they are fully appreciated by the market at current valuations. The high debt level introduces a tangible risk that tempers bullish enthusiasm, making the near-term path likely one of consolidation within its recent trading range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
5 analysts
Implied Upside
—
vs. current price
Analyst Count
5
covering this stock
Price Range
$0 - $0
Analyst target range
No sufficient analyst coverage available.
Bulls vs Bears: PM Investment Factors
Philip Morris presents a classic dichotomy: a financially strong company with a clear growth path in smoke-free products, weighed down by significant leverage and sector-specific risks. Its defensive characteristics and income appeal are balanced against the challenges of a declining core business and high valuation multiples on sales.
Bullish
- Strong Smoke-Free Transition: Dominant brands Iqos and Zyn position PMI for growth in reduced-risk products.
- Robust Profitability & Cash Flow: High net margin (20.66% Q4) and strong FCF ($10.66B TTM) support dividends.
- Attractive Forward Valuation: Forward P/E of 17.97 suggests earnings growth is expected and priced reasonably.
- High Dividend Yield: Dividend yield of 3.46% provides income, supported by a 76% payout ratio.
Bearish
- High Financial Leverage: Negative D/E ratio (-4.89) and negative ROE (-113.55%) signal significant debt burden.
- Regulatory & ESG Risks: Tobacco industry faces persistent regulatory headwinds and societal pressure.
- Valuation Premium on Sales: High P/S (6.14) and EV/Sales (7.48) ratios indicate premium pricing.
- Recent Price Weakness: Stock down 11.5% over past month, underperforming S&P 500.
PM Technical Analysis
The stock's overall trend over the past six months shows a gain of 4.71%, rising from $157.91 on October 2, 2025, to $165.34 on March 31, 2026, though it has experienced significant volatility. In the short term, the stock declined 11.50% over the past month but gained 3.08% over the past three months, indicating recent weakness but positive momentum over a slightly longer horizon. The current price of $165.34 is positioned approximately 21.8% above its 52-week low of $142.11 and 13.6% below its 52-week high of $191.30, suggesting it is in the upper-mid range of its annual trading band.
Beta
0.40
0.40x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$142-$191
Price range past year
Annual Return
-0.5%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | -14.4% | -3.7% |
| 3m | -1.9% | -4.1% |
| 6m | +2.6% | -2.1% |
| 1y | -0.5% | +16.1% |
| ytd | -1.9% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
Revenue for Q4 2025 was $10.36 billion, representing a year-over-year growth of 6.76% from the prior year's Q4. Profitability is strong, with a net margin of 20.66% for the quarter, supported by a gross margin of 65.64% and an operating margin of 32.55%. The company's financial health shows a high debt-to-equity ratio of -4.89, indicating significant financial leverage, but it maintains robust cash generation with free cash flow over the trailing twelve months of $10.66 billion. Operational efficiency is mixed, with a strong Return on Assets (ROA) of 15.96% but a negative Return on Equity (ROE) of -113.55%, largely a function of its negative shareholder equity.
Quarterly Revenue
$10.4B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Given the company's positive net income, the primary valuation metric used is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 21.99, while the forward P/E is 17.97, suggesting the market expects future earnings growth. The Price-to-Sales (P/S) ratio is 6.14, and the Enterprise Value-to-Sales (EV/Sales) is 7.48, providing additional context on its sales valuation. Peer comparison data is not available in the provided inputs.
PE
22.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -81x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
The primary financial risk is the company's elevated leverage, as evidenced by a debt-to-equity ratio of -4.89 and a deeply negative Return on Equity. This high debt load could constrain financial flexibility, especially in a rising interest rate environment. The company's core business faces secular decline risks from anti-smoking regulations and shifting consumer preferences, though its investment in reduced-risk products like Iqos and Zyn aims to mitigate this. Market risks include valuation sensitivity; the stock trades at premium sales multiples (P/S of 6.14) and has shown volatility, with a recent 11.5% monthly drop. Furthermore, the low beta of 0.395, while defensive, may also indicate limited participation in strong bull markets, as seen in its 1-year underperformance versus the S&P 500.
FAQ
The key risks are financial and sector-specific. The company has high leverage, with a debt-to-equity ratio of -4.89 and a negative ROE. The tobacco industry faces persistent regulatory, litigation, and ESG-related headwinds. There is also execution risk in transitioning revenue from declining cigarettes to growth categories like heated tobacco and nicotine pouches.
Based on the provided data, a 12-month base case forecast suggests a trading range of $165 to $185, centered around the current price. This assumes steady execution of the smoke-free strategy and maintenance of the current forward P/E multiple. The bull case could see a retest of the 52-week high ($191) and beyond, while the bear case aligns with a retest of the 52-week low ($142) if significant headwinds emerge.
PM's valuation is mixed. It appears reasonably valued on a forward earnings basis (P/E of 17.97), but carries a premium on sales (P/S of 6.14). Compared to its own 52-week range, the current price is 13.6% below its high, suggesting it is not excessively overvalued. The forward P/E being lower than the trailing P/E (21.99) indicates the market is pricing in future growth.
PM is a suitable buy primarily for income-seeking investors comfortable with sector risks. Its 3.46% dividend yield is supported by strong cash flow, and its forward P/E of 17.97 suggests reasonable valuation for expected earnings growth. However, high financial leverage and regulatory challenges mean it may not be an ideal growth stock for all portfolios.
PM is more suitable for a long-term investment horizon. The company's transition to smoke-free products is a multi-year journey, and its value proposition is anchored by a reliable dividend. Short-term price movements can be volatile, as seen in the recent 11.5% monthly drop, but the low beta (0.395) and defensive nature provide stability for long-term holders seeking income.